Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LGK974 + PDR001
- Development stage
- Unknown
- Lead developer
- Novartis
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
**LGK974 + PDR001** is a combination investigational cancer therapy consisting of LGK974, a small molecule inhibitor of the enzyme *porcupine* (critical for activating Wnt signaling), and PDR001 (spartalizumab), a monoclonal antibody targeting PD-1. LGK974 inhibits Wnt signaling by blocking palmitoylation and secretion of Wnt ligands, and is intended for use in Wnt-ligand dependent cancers. PDR001 acts as an immune checkpoint inhibitor by blocking the programmed cell death protein 1 (PD-1) pathway, thereby enhancing the anti-tumor immune response. This combination has been investigated for advanced malignancies, including melanoma, lung squamous cell carcinoma, head and neck squamous cell carcinoma, esophageal squamous cell carcinoma, cervical squamous cell carcinoma, and triple-negative breast cancer, particularly in patients refractory to prior anti-PD-1 treatment[1][3][5].
- Other names
- LGK974 + PDR001WNT974 + spartalizumab
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)PORCN (Porcupine protein)
Beyond the preview
Go deeper on LGK974 + PDR001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LGK974 + PDR001.